N

Nurix Therapeutics

Drug discovery targeting ubiquitin E3 ligases

Senior Analyst - FP&A

Corporate Finance & FP&AConfirmed live in the last 24 hours
Full-timeBrisbane, CA, USA$130k - $158.9k

About the Job

Requirements

  • At least 3 years of experience in an FP&A or Finance function; biotech or pharmaceutical experience is a plus.
  • A bachelor's degree in Finance, Economics, Accounting, or a related field.
  • High proficiency in Excel and PowerPoint.
  • Ability to work with minimal supervision in a demanding environment.
  • Strong attention to detail, cross-functional partnering, problem-solving, and time-management abilities.
  • Proactive, deadline-oriented, and self-starting approach.

Responsibilities

  • Own budgeting and forecasting for Research and G&A in partnership with department and functional leaders.
  • Deliver timely, accurate quarterly reporting and budget-versus-actual analysis for assigned areas with clear variance commentary, and partner with the business monthly to review forecast changes.
  • Manage the quarterly accrual close for Research, working with business partners and external vendors to develop and validate accruals in line with SOX controls and GAAP.
  • Own revenue recognition for Research collaboration agreements under ASC 606, partnering with Accounting.
  • Support annual financial planning and long-range planning processes.
  • Partner across Finance, Accounting, Research, and G&A to support decision-making and ad hoc analysis.
  • Build and improve financial models and scenario analyses for Research and G&A, including program-level budget and resource-allocation scenarios.
  • Evaluate current processes and systems and drive efficiency improvements, including through automation and AI tooling.

Desired Qualifications

  • Biotech or pharmaceutical experience.
  • Experience with Planful or a comparable FP&A planning platform and NetSuite or a comparable ERP.
  • Interest in improving processes through automation or AI.
  • CPA or MBA.

About the Company

Nurix Therapeutics

Drug discovery targeting ubiquitin E3 ligases

Nurix Therapeutics develops drugs that use the body's own protein-degradation system to treat diseases. Its core approach is to control ubiquitin E3 ligases, enzymes that tag unwanted proteins for breakdown in cells. By modulating these ligases, Nurix aims to create therapeutics, especially small-molecule immuno-oncology agents, that can selectively remove disease-related proteins in cancer and other serious conditions. The company operates by discovering and developing drug candidates and earning revenue through partnerships, licensing, and potential future sales of its medicines. Unlike many biotech firms that target single proteins, Nurix focuses on the protein-degradation pathway to influence multiple disease processes through carefully designed molecules. The goal is to bring new cancer treatments and other therapies to patients by advancing its degrader-based drugs through research, collaboration, and development toward commercial use.

Company size
201-500
Company stage
IPO
Headquarters
Brisbane, CA
Founded
2012

Recently Posted Jobs

Explore more opportunities at Nurix Therapeutics

See more jobs